Criticalkare Pharma

Synagis 50mg Injection contains the active substance Palivizumab, a monoclonal antibody used primarily to prevent severe respiratory syncytial virus (RSV)-related lower respiratory tract infections in high-risk children. 
Synagis 50mg Injection is prescribed to infants and young children at high risk for severe RSV infection, including those born prematurely (≤35 weeks gestational age), those with broncho pulmonary dysplasia (BPD), and children with hemodynamically significant congenital heart disease (CHD). It works by inhibiting the RSV F protein, preventing the virus from entering and infecting healthy cells. 
Before starting treatment with Synagis 50mg Injection, inform your doctor if your child has any history of allergies or bleeding disorders, as well as any other medications they are currently taking. While Synagis 50mg Injection is generally well-tolerated, regular monitoring is recommended, particularly for any signs of hypersensitivity reactions or coagulation disorders.
Uses
Synagis 50mg Injection is a monoclonal antibody developed to prevent severe RSV-related lower respiratory tract disease in high-risk children. It works by inhibiting the RSV F protein, blocking the virus from entering cells, and has proven to be safe and effective in specific high-risk patient populations.
Synagis 50mg Injection is used to prevent RSV infection in children at high risk, including:
Children with bronchopulmonary dysplasia (BPD)Infants born prematurely (≤35 weeks gestational age)Children with hemodynamically significant congenital heart disease (CHD)
Storage
Store between 2°C and 8°C (36°F and 46°F) in its original container. Do not freeze. Use before expiration.Administered by healthcare professionals as an intramuscular injection. Use with caution in children with thrombocytopenia or coagulation disorders.Discontinue immediately if anaphylaxis or severe allergic reactions occur. Provide appropriate emergency treatment.It may interfere with certain RSV diagnostic tests (e.g., antigen detection-based assays). RT-PCR is preferred for confirmation.
Side Effects
FeverRashInjection site reactions (e.g., pain, swelling)Mild hypersensitivity reactions (e.g., urticaria, pruritus)Anaphylaxis (severe allergic reactions, including shock)Respiratory issues (e.g., dyspnea, respiratory failure, cyanosis)Hypotension (low blood pressure)Severe thrombocytopenia (low platelet count)Coagulation disorders (increased bleeding risk)Severe hypersensitivity reactions (e.g., angioedema, unresponsiveness)